Pediatric Hematology Oncology Program
Area of Interest
Dr. Blatt’s research efforts and scholarly activities, while somewhat eclectic and broad-based, always have included a focus on experimental therapeutics. Over the past 10 years, her focus has been on the study of vascular anomalies. She is the PI for Novartis’ Phase II Alpelisib trial for PROS disorders and have enrolled the first two patients in the US on that trial. Dr. Blatt’s is also a member of UNC Lineberger Cancer Center’s DSMC protocol regulatory committee and has participated in numerous institutional and Children’s Oncology Group therapy and biology protocols over the past 35 years. In addition to this, she has developed an interest in drug repurposing for pediatrics and in the care of patients with vascular anomalies. In 2014, Dr. Blatt’s co-developed the Children’s Pharmacy Collaborative (CPC) with colleagues at UNC’s School of Pharmacy (Drs. A. Tropsha and W. Janzen) and at the Cleveland Clinic (Dr. S. Corey), a comprehensive database of drugs for which there are dosing and scheduling data in children, and which includes information on primary and new indications, FDA status, chemical structure, mechanisms of action. This database was a resource for a 2017 publication with NCATS in which they used high throughput technology to study many of these drugs for repurposing potential on an array of pediatric solid tumors. More recently, Dr. Blatt’s has been applying her experiences as a pediatric oncologist to develop new therapies for vascular malformations. She has also collaborated with UNC’s Department of Cell Biology and Physiology (K. Caron, PhD) on Notch experession and the role of Notch inhibitors in the treatment of these disorders and with the Department of Biomedical Engineering (W. Polacheck, PhD) on in vitro models of vasculogenesis. She is also a member of the American Society of Pediatric Hematology Oncology’s Vascular Anomalies Special Interest Group where she chairs the Practice Work Group, and of the International Society for the Study of Vascular Anomalies.